Physician profile
Ared Garan
NPI 1508846585
$1,274.12
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $197 · 2021: $366 · 2022: $100 · 2023: $157 · 2024: $29.63 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.11 | 2019-2022 | |
| Allergan, INC. | $131.17 | 2019 | |
| Astellas Pharma US INC | $93.93 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $89.27 | 2019-2022 | |
| Hologic Sales and Service, LLC | $82.59 | 2020-2023 | Thinprep 2000 Processor |
| Baxter Healthcare | $72.70 | 2025 | Perclot |
| Pfizer INC. | $59.97 | 2023 | |
| Daiichi Sankyo INC. | $58.80 | 2021 | |
| Duchesnay USA Incorporated | $58.68 | 2019 | |
| Smith+Nephew, INC. | $31.24 | 2021 | |
| Myovant Sciences INC. | $24.17 | 2021 | |
| Agile Therapeutics, INC. | $18.40 | 2023 | Twirla |
| Merck Sharp & Dohme LLC | $16.18 | 2019 | |
| Scynexis, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ared Garan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.